Nyumbani › Leukemia ya Lymphoblastic ya Ghafla › Ohio › Cincinnati
Majaribio ya kliniki ya Leukemia ya Lymphoblastic ya Ghafla katika Cincinnati, OH
Masomo 12 ya Leukemia ya Lymphoblastic ya Ghafla yanatafuta washiriki katika vituo vya Cincinnati na maeneo yake (ndani ya takriban maili 30). Fungua somo kuona nani anaweza kujiunga na jinsi ya kuwasiliana na timu ya utafiti.
Maandishi rasmi ya utafiti (Kiingereza)
Unavutia washiriki kwa utafiti hapa? Weka juu ya ukurasa huu — $99 kwa siku 30 →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
InaajiriUtafiti wa uchunguziWajitolea wenye afya wanakaribishwa
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Oncology Hematology Care Inc-Kenwood, Cincinnati
- Bethesda North Hospital, Cincinnati
- na zaidi ya 3
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
InaajiriUtafiti wa uchunguzi
- Cincinnati Children's Hospital Medical Center, Cincinnati
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
InaajiriHatua 2
- Oncology Hematology Care, Cincinnati
- Cincinnati Children's Hospital Medical Center, Cincinnati
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
InaajiriHatua 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
InaajiriHatua 1/2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
InaajiriHatua 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
InaajiriUtafiti wa uchunguzi
- Children's Hospital Medical Center, Cincinnati
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
InaajiriUtafiti wa uchunguzi
- Cincinnati Children's Hospital, Cincinnati
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
InaajiriHatua 1/2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
InaajiriUtafiti wa uchunguzi
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
InaajiriHatua 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
InaajiriHatua 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
Majaribio ya Leukemia ya Lymphoblastic ya Ghafla katika miji mingine
- Houston, TXUtafiti 28
- New York City, NYUtafiti 24
- Baldwin Park, CAUtafiti 21
- Seattle, WAUtafiti 21
- Chicago, ILUtafiti 19
- Atlanta, GAUtafiti 19
- Memphis, TNUtafiti 16
- Philadelphia, PAUtafiti 16
- Washington, DCUtafiti 16
- Boston, MAUtafiti 15
- Los Angeles, CAUtafiti 14
- Durham, NCUtafiti 13
Masomo mengine katika Cincinnati
- Saratani ya Mapafu Isiyo na Selu NdogoUtafiti 35
- Saratani (aina zote)Utafiti 27
- Saratani ya MatitiUtafiti 25
- Kushindwa kwa MoyoUtafiti 24
- Kansari ya kolorektaliUtafiti 21
- Leukemia ya Myeloid ya GhaflaUtafiti 20
- Saratani ya MetastasiUtafiti 20
- Kansari ya MayaiUtafiti 19
- Saratan ya MapafuUtafiti 19
- UnenepuUtafiti 19
- Saratani ya ProstateUtafiti 18
- Multiple MyelomaUtafiti 17
Kutoka ClinicalTrials.gov, data iliyopatikana 5 Okt 2026. Kila utafiti una masharti yake ya kufaa; timu ya utafiti huamua nani anaweza kujiunga.